© Drug Hunter Inc. 2018-2023
Home > PF-06843195
oral PI3K_-selective kinase inhibitor prodrug
preclinical candidate for breast cancer
from mining of prior PI3K inh., SBDD, and opt.
J. Med. Chem., Dec. 24, 2020
Pfizer, San Diego, CA
Pfizer oral PI3ka-selective kinase inhibitor prodrug
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
Molecules of the Month
Molecule of the Year